舒脑欣滴丸联合洛美利嗪治疗偏头痛的临床研究

目的探讨舒脑欣滴丸联合盐酸洛美利嗪胶囊治疗偏头痛的临床疗效。方法选择2019年2月—2019年6月在天津市北辰医院治疗的偏头痛患者88例,根据用药的差别分为对照组(44例)和治疗组(44例)。对照组口服盐酸洛美利嗪胶囊,5mg/次,2次/d;治疗组在对照组基础上口服舒脑欣滴丸,4粒/次,3次/d。两组患者均经过4周治疗。观察两组患者临床疗效,同时比较治疗前后两组患者症候评分,PSQI、SF-36和VAS评分,血清环氧化酶-2(COX-2)、溶血磷脂酸(LPA)、神经元特异性烯醇酶(S-NSE)、同型半胱氨酸(Hcy)、血栓烷素2(TXB2)和5-羟色胺(5-HT)水平。结果治疗后,对照组临床有效率为81.82%,显著低于治疗组的97.73%,两组比较差异具有统计学意义(P<0.05)。经治疗,两组患者症候评分、PSQI和VAS评分均明显下降(P<0.05),而SF-36评分明显升高(P<0.05),且治疗组这些评分明显好于对照组(P<0.05)。经治疗,两组患者血清COX-2、LPA、S-NSE、Hcy、TXB2水平均明显降低(P<0.05),而5-HT水平均明显升高(P<0.05),且治疗组患者血清学指标水平明显好于对照组(P<0.05)。结论舒脑欣滴丸联合盐酸洛美利嗪胶囊治疗偏头痛可有效改善患者临床症状,提高患者睡眠及生活质量,具有一定的临床推广应用价值。

Clinical study on Shunaoxin Dropping Pills combined with lomerizine in treatment of migraine

Objective To explore the clinical efficacy of Shunaoxin Dropping Pills combined with lomerizine in treatment of Migraine. Methods Patients (88 cases) with migraine in Tianjin Beichen Hospital from February 2019 to June 2019 were divided into control (44 cases) and treatment (44 cases) groups based on different treatments. Patients in the control group were po administered with Lomerizine Hydrochloride Capsules, 5 mg/time, twice daily. Patients in the treatment group were po administered with Shunaoxin Dropping Pills on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the scores of symptom, PSQI, SF-36 and VAS, the serum levels of COX-2, LPA, S-NSE, Hcy, TXB2 and 5-HT in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.82%, which was significantly lower than 97.73% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the scores of symptom, PSQI and VAS in two groups were significantly decreased (P<0.05), but the SF-36 scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of COX-2, LPA, S-NSE, Hcy and TXB2 in two groups were significantly decreased (P<0.05), but the 5-HT levels were significantly increased (P<0.05), and these serological indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Shunaoxin Dropping Pills combined with lomerizine in treatment of migraine can effectively improve the clinical symptoms of migraine patients, and improve the sleep and quality of life of patients, which has a certain clinical application value.